[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600358":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":29,"centralContacts":33,"locations":39,"responsibleParty":58,"collaborators":28,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":28,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":28,"studyType":73,"phases":74,"briefSummary":77,"conditions":78,"keywords":81,"overallStatus":41,"whyStopped":28,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"University of Minnesota","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Single Dose, Day 0","EXPERIMENTAL","CMVIG 150 mg\u002Fkg x 1 at Day 0. Belatacept will be administered per standard of care (IV infusion over 30 minutes in an outpatient specialty infusion center). Cytogam will be administered according to the assigned dosing regimen starting 30 minutes after completion of Belatacept infusion.",[13],"Drug: Cytogam",{"label":15,"type":10,"description":16,"interventionNames":17},"Two Doses, One Week","CMVIG 150 mg\u002Fkg x 2. Dose #1: Day 0, Dose #2: Day 7. Belatacept will be administered per standard of care (IV infusion over 30 minutes in an outpatient specialty infusion center). Cytogam will be administered according to the assigned dosing regimen starting 30 minutes after completion of Belatacept infusion.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Two Doses, Four Weeks","CMVIG 150 mg\u002Fkg x 2. Dose #1: Day 0, Dose #2: Day 28. Belatacept will be administered per standard of care (IV infusion over 30 minutes in an outpatient specialty infusion center). Cytogam will be administered according to the assigned dosing regimen starting 30 minutes after completion of Belatacept infusion.",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Cytogam","Cytogam is used for the prevention of cytomegalovirus (CMV) disease in kidney, lung, liver, pancreas, heart and bone marrow transplantation. We do not yet have data about how much cytogam reduces CMV in blood, or how quickly it reduces CMV in blood.",[9,19,15],null,[30],{"name":31,"affiliation":5,"role":32},"Vanessa Humphreville, MD","PRINCIPAL_INVESTIGATOR",[34],{"name":35,"role":36,"phone":37,"phoneExt":28,"email":38},"Elise Reed","CONTACT","612-624-9695","surgcto@umn.edu",[40],{"facility":5,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Minneapolis","Minnesota","55455","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-93.26384,44.97997,{"lat":51,"lon":50},[54,57],{"name":55,"role":36,"phone":37,"phoneExt":28,"email":56},"Mary Farnsworth","ewigx005@umn.edu",{"name":31,"role":32,"phone":28,"phoneExt":28,"email":28},{"type":59,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100600358","phase-1-cmvig-prophylaxis-in-belatacept-conversion-kidney-transplant-recipients-100600358",false,"NCT07096453","CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients","CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients: a PK Pilot Study","Inclusion Criteria:\n\n* Adult (18-70 year old) kidney transplant recipients\n* Patients transitioning from conventional CNI-based immunosuppression to co-stimulatory blockade (belatacept) immunosuppression OR patients who are stable on belatacept immunosuppression at the time of initial CYTOGAM infusion\n* CMV Ig Seronegative Recipient who received a CMV Ig seropositive Donor\n* EBV IgG Positive\n\nExclusion Criteria:\n\n* Pregnant people\n* Subjects unwilling to sign consent and complete follow up visits\n* Subjects with IgA immunodeficiency\n* Subjects who are receiving IgG therapy or who have received IgG therapy within two months of study enrollment\n* Patients who do not speak English and would need a translator and translated consent materials in order to obtain informed consent","ALL","18 Years","70 Years",{"count":71,"type":72},30,"ESTIMATED","INTERVENTIONAL",[75,76],"PHASE1","PHASE2","The purpose of this study is to study how CMVIG interacts with the body and to see if it might work to prevent kidney transplant patients from becoming infected with CMV.",[79,80],"Kidney Transplant; Complications","CMV",[82,83],"Kidney transplant","CMV prevention","2025-10-29",{"date":86,"type":87},"2025-10-31","ACTUAL",{"date":89,"type":87},"2025-10-02",{"date":91,"type":72},"2027-08",{"name":5,"class":6},1]